source
- Alkermes reports early proof-of-concept for orexin-2 drug in ADHDAlkermes announced early-stage trial results for ALKS 7290, an orexin‑2 receptor agonist originally being developed for narcolepsy, showing proof of concept in ADHD. The study reported dose‑depend…
- HHS rolls out new FDA rule to allow non-animal testing methods in drug developmentThe Department of Health and Human Services announced a new set of strategies aimed at shifting drug development away from animal testing toward human-based research methods. The FDA issued a fina…